

UNIV.-PROF. DR. MED. STAVROS KONSTANTINIDES, PhD, FESC, FRCP(Glasg)

Position	Professor, Clinical Trials, and Medical Director
Institution & Department	Centre for Thrombosis and Haemostasis, University Medical Centre Mainz Langenbeckstr. 1, Building 403, 55131 Mainz Phone: +49 6131 17 8382, email: stavros.konstantinides@unimedizin-mainz.de
Career Path	<p>2014–today: Medical Director, Centre for Thrombosis and Haemostasis Mainz</p> <p>2012–today: Appointed Professor for Clinical Trials, Centre for Thrombosis and Haemostasis, University Medical Centre Mainz, Germany</p> <p>2009–today: Appointed Professor of Cardiology, Democritus University of Thrace, Greece</p> <p>2003 – 2009: Associate Professor of Medicine and managing senior physician, Dept. of Cardiology and Pulmonary Medicine, University Medical Centre Göttingen</p> <p>2000-2002: Associate Professor of Medicine, Department of Cardiology and Pulmonary Medicine, University Medical Centre Göttingen</p> <p>1999–2000: Research Associate with David J. Loskutoff, Ph.D., Department of Vascular Biology, The Scripps Research Institute, La Jolla, California, USA</p> <p>1998-1999: Assistant Professor of Medicine, Department of Cardiology and Pulmonary Medicine, University Medical Centre Göttingen, Germany</p> <p>1998: Board Certification in Cardiology</p> <p>1998: Habilitation in Internal Medicine, University of Freiburg</p> <p>1997: Board Certification in Internal Medicine</p> <p>1991-1993: Doctoral thesis at the University of Freiburg: “Surgical Closure vs. Medical Treatment of Atrial Septal Defect in Adults: Long-Term Follow-up”; grade: <i>magna cum laude</i>; published in the <i>New England Journal of Medicine</i> 1995</p> <p>1990-1997: Clinical training in Internal Medicine and Cardiology, Department of Cardiology and Angiology, University of Freiburg, Germany</p> <p>1988-1990: Military service (Greece)</p> <p>1982-1987: Medical School, Aristotle University of Thessalonica, Greece</p>
Honors and Awards	<p>2019: Visiting Professor, University of Belgrade, Serbia</p> <p>2017: Theodor Naegeli-Preis für Thromboseforschung, Switzerland</p> <p>2017: Jaap de Graeff Medal, Leiden University Medical Center, The Netherlands</p> <p>2015: Honorary Fellow, Royal College of Physicians & Surgeons of Glasgow, UK</p> <p>2015: Honorary Fellow, Romanian Society of Cardiology</p> <p>2004: Novartis Foundation Prize</p> <p>2001: William Harvey Prize, International Society on Thrombosis & Haemostasis</p>
Publications	<p>Scopus: publications 427; citations 29,704; h-index 72</p> <p>Google Scholar: publications 560; citations 59,500; h-index 83</p> <p>Selected publications:</p> <ul style="list-style-type: none">• Valerio V, Mavromanoli AC, [...], Konstantinides SV (corresp. author); FOCUS Investigators. Chronic thromboembolic pulmonary hypertension and impairment after pulmonary embolism: the FOCUS study. <i>Eur Heart J</i> 2022. doi: 10.1093/eurheartj/ehac206.• Klok FA, Toenges G, [...], Konstantinides SV. Early switch to oral anticoagulation in patients with acute intermediate-risk pulmonary embolism (PEITHO-2): a multinational, multicentre trial. <i>Lancet Haematol</i> 2021;8(9): e627-e636.• Barco S, Mahmoudpour SH, [...], Konstantinides SV. Trends in mortality related to pulmonary embolism in the European Region, 2000-15: analysis of vital registration data from the WHO Mortality Database. <i>Lancet Respir Med</i> 2020;8:277-287.• Barco S, Schmidtmann I, [...], Wild PS, Konstantinides SV, Lankeit M; HoT-PE Investigators. Early discharge and home treatment of patients with low-risk pulmonary embolism with the oral factor Xa inhibitor rivaroxaban: an international multicentre single-arm clinical trial. <i>Eur Heart J</i> 2020;41:509-518.• Keller K, Hobohm L, [...], Konstantinides SV, Lankeit M. Trends in thrombolytic treatment and outcomes of acute pulmonary embolism in Germany. <i>Eur Heart J</i> 2020;41:522-529.• Barco S, [...], Konstantinides SV, Meyer G. Prognostic value of right ventricular dysfunction or elevated cardiac biomarkers in patients with low-risk pulmonary

embolism: a systematic review and meta-analysis. *Eur Heart J* 2019;40:902-910.

- **Konstantinides S**, Vicaut E, Danays T, [...], Meyer G. Impact of thrombolytic therapy on the long-term outcome of intermediate-risk pulmonary embolism. *J Am Coll Cardiol* 2017;69(12):1536-1544.
- Meyer G, Vicaut E, [...], **Konstantinides S**. Fibrinolysis for patients with acute intermediate-risk pulmonary embolism. *N Engl J Med* 2014;370: 1402-1411.
- Verhoef TJ, Ragia G, de Boer A, **Konstantinides S**, et al; the EU-PACT Group. A randomized trial of genotype-guided dosing of acenocoumarol and phenprocoumon. *N Engl J Med* 2013;369(24):2304-2312
- **Konstantinides S**, Geibel A, Heusel G, et al. A randomized trial comparing alteplase plus heparin with heparin alone in patients with acute major pulmonary embolism. *N Engl J Med* 2002;347:1143-1150

Leading/ Coordinating Investigator of Multicentre Clinical Trials

- Pulmonary Embolism International Trial (**PEITHO**)-3 - A reduced dose of thrombolytic treatment for patients with intermediate high-risk acute pulmonary embolism: randomized controlled trial. EudraCT 2018-000816-96 (ongoing).
- Randomized trial of ultrasound-facilitated, catheter-directed thrombolysis versus anticoagulation for acute intermediate-high risk pulmonary embolism: The higher-risk pulmonary embolism thrombolysis study (**HI-PEITHO**). NCT04790370 (ongoing).
- Home Treatment of Patients with Low-Risk Pulmonary Embolism with the Oral Factor Xa Inhibitor Rivaroxaban (**HoT-PE**). EudraCT 2013-001657-28 (completed).
- Pulmonary Embolism International Trial (**PEITHO**)-2 - A prospective, multicenter, single-arm management study to investigate the safety and efficacy of low molecular weight heparin followed by dabigatran for the treatment of acute intermediate-risk pulmonary embolism. NCT02596555 (completed).
- Pulmonary Embolism International Trial (**PEITHO**) - A prospective, randomised, double-blind, placebo-controlled, parallel-group comparison trial evaluating the efficacy and safety of single i.v. bolus tenecteplase plus standard anticoagulation as compared with standard anticoagulation in normotensive patients with acute pulmonary embolism and right ventricular dysfunction. NCT00639743 (completed).
- Effect of Otamixaban Versus Unfractionated Heparin + Eptifibatide in Patients With Unstable Angina/Non ST Elevation Myocardial Infarction Undergoing Early Invasive Strategy. NCT01076764 (completed).
- Management Strategies and Prognosis of Pulmonary Embolism (**MAPPET**) - 3 – A multicentre double-blind randomised trial comparing alteplase with heparin alone in normotensive patients with evidence of right ventricular dysfunction or pressure overload (completed; published 2002).

Third Party Funding

- **DFG** Clinical Trials Programme 2020- (KO1939/3-1): Multinational PEITHO-III Trial
- **BMBF** 2012-2015 and 2015-2020 (01EO1003 & 01EO1503): Set-up of a multicentre academic clinical trials programme, CTH, University Medical Centre Mainz
- **Boehringer Ingelheim** 2015-2019: Institutional support of the academic multicentre PEITHO-2 trial
- **Bayer AG**, 2014-2018: Institutional support of the academic HoT-PE trial
- **BMBF** Clinical Trials Progr. 2008-2012 (01KG0802): Multinational PEITHO trial

International cooperations

1) Prof. Walter Ageno, University of Insubria, Italy; 2) Prof. Guy Meyer, Université Paris Descartes, France; 3) Prof. Samuel Z. Goldhaber, Harvard Medical School, Boston, MA, US; 4) Prof. Ander Cohen and Prof. Berverley Hunt, Guy's and St. Thomas' Trust, London, UK; 5) Prof. Menno V. Huisman, Leiden University Medical Center, The Netherlands; 6) Prof. Irene Lang, Medical University of Vienna, Austria; 7) Prof. Marion Delcroix, University of Leuven, Belgium; 8) Prof. Marc Righini, Geneva University Hospital, Switzerland; 9) Prof. Nils Kucher, Zurich, Switzerland; 10) Prof. David Jiménez, Ramon y Cajal Hospital, Madrid, Spain; 11) Prof. Piotr Pruszczyk, Medical University of Warsaw, Poland; 12) Prof. Antoniu Petris, University of Iași, Romania; 13) Prof. Branislav Stefanovic, University of Belgrade, Serbia; 14) Prof. Benjamin Brenner, Rambam Health Care Campus, Haifa, Israel.